Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study

Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study

Abstract Heterogeneity has been demonstrated to be a predictor of treatment failure and drug resistance. Our study aimed to investigate imaging parameters, including tumor heterogeneity, as prognostic factors of response to 500 mg fulvestrant using 18F-FDG PET/CT. Twenty-seven estrogen receptor (HR)...

Full description

Bibliographic Details
Main Authors: Yannan Zhao, Cheng Liu, Yingjian Zhang, Chengcheng Gong, Yi Li, Yizhao Xie, Bingrui Wu, Zhongyi Yang, Biyun Wang
Format: Article
Language:English
Published: Nature Portfolio 2018-09-01
Series:Scientific Reports
Subjects:
Metastatic Breast Cancer Patients
Total Lesion Glycolysis (TLG)
Intra-tumor Heterogeneity
Heterogeneity Parameter
Metabolic Tumor Volume
Online Access:https://doi.org/10.1038/s41598-018-32745-z

Internet

https://doi.org/10.1038/s41598-018-32745-z

Similar Items